New Thiazolidine-4-One Derivatives as SARS-CoV-2 Main Protease Inhibitors

It has been more than four years since the first report of SARS-CoV-2, and humankind has experienced a pandemic with an unprecedented impact. Moreover, the new variants have made the situation even worse. Among viral enzymes, the SARS-CoV-2 main protease (M<sup>pro</sup>) has been deemed...

Full description

Bibliographic Details
Published in:Pharmaceuticals
Main Authors: Antonella Messore, Paolo Malune, Elisa Patacchini, Valentina Noemi Madia, Davide Ialongo, Merve Arpacioglu, Aurora Albano, Giuseppe Ruggieri, Francesco Saccoliti, Luigi Scipione, Enzo Tramontano, Serena Canton, Angela Corona, Sante Scognamiglio, Annalaura Paulis, Mustapha Suleiman, Helmi Mohammed Al-Maqtari, Fatma Mohamed A. Abid, Sarkar M. A. Kawsar, Murugesan Sankaranarayanan, Roberto Di Santo, Francesca Esposito, Roberta Costi
Format: Article
Language:English
Published: MDPI AG 2024-05-01
Subjects:
SARS-CoV-2
COVID-19
main protease
thiazolidinone derivatives
small molecules
docking studies
Online Access:https://www.mdpi.com/1424-8247/17/5/650

Internet

https://www.mdpi.com/1424-8247/17/5/650

Similar Items